Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 15 studies | 28% ± 13% | |
fibroblast | 13 studies | 26% ± 10% | |
smooth muscle cell | 12 studies | 20% ± 5% | |
astrocyte | 12 studies | 33% ± 14% | |
oligodendrocyte | 12 studies | 35% ± 13% | |
pericyte | 12 studies | 25% ± 11% | |
oligodendrocyte precursor cell | 10 studies | 30% ± 14% | |
macrophage | 8 studies | 23% ± 10% | |
dendritic cell | 7 studies | 24% ± 10% | |
epithelial cell | 7 studies | 33% ± 21% | |
endothelial cell of lymphatic vessel | 6 studies | 26% ± 10% | |
microglial cell | 6 studies | 20% ± 5% | |
monocyte | 5 studies | 22% ± 5% | |
classical monocyte | 5 studies | 23% ± 5% | |
naive B cell | 5 studies | 21% ± 6% | |
non-classical monocyte | 5 studies | 23% ± 5% | |
CD4-positive, alpha-beta T cell | 5 studies | 18% ± 2% | |
effector memory CD8-positive, alpha-beta T cell | 5 studies | 20% ± 4% | |
neuron | 5 studies | 36% ± 18% | |
interneuron | 5 studies | 34% ± 21% | |
lymphocyte | 5 studies | 29% ± 11% | |
basal cell | 5 studies | 25% ± 16% | |
gamma-delta T cell | 5 studies | 22% ± 6% | |
GABAergic neuron | 5 studies | 37% ± 15% | |
type I pneumocyte | 5 studies | 23% ± 6% | |
T cell | 4 studies | 18% ± 4% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 4 studies | 21% ± 5% | |
natural killer cell | 4 studies | 19% ± 2% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 21% ± 3% | |
abnormal cell | 4 studies | 25% ± 10% | |
myofibroblast cell | 4 studies | 23% ± 9% | |
B cell | 4 studies | 21% ± 3% | |
myeloid cell | 4 studies | 22% ± 3% | |
adipocyte | 4 studies | 22% ± 4% | |
ciliated cell | 4 studies | 28% ± 15% | |
glutamatergic neuron | 4 studies | 47% ± 14% | |
club cell | 4 studies | 23% ± 6% | |
conventional dendritic cell | 3 studies | 22% ± 4% | |
Mueller cell | 3 studies | 22% ± 7% | |
CD8-positive, alpha-beta T cell | 3 studies | 17% ± 1% | |
CD8-positive, alpha-beta memory T cell | 3 studies | 21% ± 4% | |
mature NK T cell | 3 studies | 20% ± 3% | |
luminal cell of prostate epithelium | 3 studies | 20% ± 5% | |
connective tissue cell | 3 studies | 18% ± 1% | |
ependymal cell | 3 studies | 32% ± 9% | |
type II pneumocyte | 3 studies | 22% ± 4% | |
muscle cell | 3 studies | 28% ± 13% | |
goblet cell | 3 studies | 38% ± 22% | |
transit amplifying cell | 3 studies | 36% ± 22% | |
erythroblast | 3 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5669.05 | 1445 / 1445 | 100% | 32.09 | 183 / 183 |
intestine | 100% | 5500.06 | 966 / 966 | 100% | 19.06 | 527 / 527 |
ovary | 100% | 6673.77 | 180 / 180 | 100% | 17.05 | 429 / 430 |
stomach | 100% | 3934.19 | 359 / 359 | 100% | 23.10 | 285 / 286 |
lung | 100% | 6620.68 | 578 / 578 | 99% | 17.95 | 1145 / 1155 |
breast | 100% | 4544.40 | 459 / 459 | 99% | 16.96 | 1104 / 1118 |
uterus | 100% | 6476.24 | 170 / 170 | 98% | 15.26 | 452 / 459 |
bladder | 100% | 4859.81 | 21 / 21 | 98% | 14.13 | 496 / 504 |
brain | 99% | 3256.95 | 2617 / 2642 | 99% | 14.14 | 699 / 705 |
skin | 100% | 5106.42 | 1809 / 1809 | 98% | 14.78 | 463 / 472 |
thymus | 100% | 4935.47 | 652 / 653 | 98% | 9.78 | 591 / 605 |
prostate | 100% | 4557.37 | 245 / 245 | 96% | 10.00 | 482 / 502 |
pancreas | 97% | 2061.29 | 317 / 328 | 99% | 13.11 | 176 / 178 |
adrenal gland | 100% | 2877.49 | 258 / 258 | 90% | 9.76 | 206 / 230 |
kidney | 100% | 2669.29 | 89 / 89 | 89% | 8.46 | 800 / 901 |
liver | 91% | 1465.19 | 206 / 226 | 70% | 5.33 | 286 / 406 |
adipose | 100% | 5069.55 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5827.94 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 7544.25 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3941.78 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 17.25 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 11.73 | 1 / 1 |
peripheral blood | 99% | 5039.28 | 924 / 929 | 0% | 0 | 0 / 0 |
heart | 98% | 3359.67 | 848 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 11.70 | 77 / 80 |
lymph node | 0% | 0 | 0 / 0 | 93% | 9.04 | 27 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0035196 | Biological process | miRNA processing |
GO_0009791 | Biological process | post-embryonic development |
GO_0090625 | Biological process | siRNA-mediated gene silencing by mRNA destabilization |
GO_0035279 | Biological process | miRNA-mediated gene silencing by mRNA destabilization |
GO_0035278 | Biological process | miRNA-mediated gene silencing by inhibition of translation |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_1901165 | Biological process | positive regulation of trophoblast cell migration |
GO_0060213 | Biological process | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening |
GO_0006412 | Biological process | translation |
GO_0090128 | Biological process | regulation of synapse maturation |
GO_0033962 | Biological process | P-body assembly |
GO_0006413 | Biological process | translational initiation |
GO_0031054 | Biological process | pre-miRNA processing |
GO_1900153 | Biological process | positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay |
GO_0035194 | Biological process | regulatory ncRNA-mediated post-transcriptional gene silencing |
GO_0031047 | Biological process | regulatory ncRNA-mediated gene silencing |
GO_0045947 | Biological process | negative regulation of translational initiation |
GO_0042985 | Biological process | negative regulation of amyloid precursor protein biosynthetic process |
GO_0045727 | Biological process | positive regulation of translation |
GO_0030422 | Biological process | siRNA processing |
GO_0070922 | Biological process | RISC complex assembly |
GO_0010501 | Biological process | RNA secondary structure unwinding |
GO_0010586 | Biological process | miRNA metabolic process |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0070578 | Cellular component | RISC-loading complex |
GO_0016020 | Cellular component | membrane |
GO_0036464 | Cellular component | cytoplasmic ribonucleoprotein granule |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0098794 | Cellular component | postsynapse |
GO_0030425 | Cellular component | dendrite |
GO_0000932 | Cellular component | P-body |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0016442 | Cellular component | RISC complex |
GO_0005634 | Cellular component | nucleus |
GO_0070551 | Molecular function | endoribonuclease activity, cleaving siRNA-paired mRNA |
GO_0004521 | Molecular function | RNA endonuclease activity |
GO_0000340 | Molecular function | RNA 7-methylguanosine cap binding |
GO_0001046 | Molecular function | core promoter sequence-specific DNA binding |
GO_0003727 | Molecular function | single-stranded RNA binding |
GO_0098808 | Molecular function | mRNA cap binding |
GO_0035197 | Molecular function | siRNA binding |
GO_0003743 | Molecular function | translation initiation factor activity |
GO_0000993 | Molecular function | RNA polymerase II complex binding |
GO_0035925 | Molecular function | mRNA 3'-UTR AU-rich region binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0003723 | Molecular function | RNA binding |
GO_0003725 | Molecular function | double-stranded RNA binding |
GO_0090624 | Molecular function | endoribonuclease activity, cleaving miRNA-paired mRNA |
GO_0035198 | Molecular function | miRNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | AGO2 |
Protein name | Protein argonaute-2 (Argonaute2) (hAgo2) (EC 3.1.26.n2) (Argonaute RISC catalytic component 2) (Eukaryotic translation initiation factor 2C 2) (eIF-2C 2) (eIF2C 2) (PAZ Piwi domain protein) (PPD) (Protein slicer) Argonaute RISC catalytic component 2 |
Synonyms | EIF2C2 |
Description | FUNCTION: Required for RNA-mediated gene silencing (RNAi) by the RNA-induced silencing complex (RISC). The 'minimal RISC' appears to include AGO2 bound to a short guide RNA such as a microRNA (miRNA) or short interfering RNA (siRNA). These guide RNAs direct RISC to complementary mRNAs that are targets for RISC-mediated gene silencing. The precise mechanism of gene silencing depends on the degree of complementarity between the miRNA or siRNA and its target. Binding of RISC to a perfectly complementary mRNA generally results in silencing due to endonucleolytic cleavage of the mRNA specifically by AGO2. Binding of RISC to a partially complementary mRNA results in silencing through inhibition of translation, and this is independent of endonuclease activity. May inhibit translation initiation by binding to the 7-methylguanosine cap, thereby preventing the recruitment of the translation initiation factor eIF4-E. May also inhibit translation initiation via interaction with EIF6, which itself binds to the 60S ribosomal subunit and prevents its association with the 40S ribosomal subunit. The inhibition of translational initiation leads to the accumulation of the affected mRNA in cytoplasmic processing bodies (P-bodies), where mRNA degradation may subsequently occur. In some cases RISC-mediated translational repression is also observed for miRNAs that perfectly match the 3' untranslated region (3'-UTR). Can also up-regulate the translation of specific mRNAs under certain growth conditions. Binds to the AU element of the 3'-UTR of the TNF (TNF-alpha) mRNA and up-regulates translation under conditions of serum starvation. Also required for transcriptional gene silencing (TGS), in which short RNAs known as antigene RNAs or agRNAs direct the transcriptional repression of complementary promoter regions. .; FUNCTION: (Microbial infection) Upon Sars-CoV-2 infection, associates with viral miRNA-like small RNA, CoV2-miR-O7a, and may repress mRNAs, such as BATF2, to evade the IFN response. . |
Accessions | Q9UKV8 E5RGG9 E5RJY2 ENST00000220592.10 [Q9UKV8-1] ENST00000523609.5 ENST00000519980.5 [Q9UKV8-2] ENST00000524328.1 |